ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis  by Blanco, Sandra et al.
Kidney International, Vol. 67, Supplement 93 (2005), pp. S10–S14
ACE inhibitors improve nephrin expression in Zucker rats with
glomerulosclerosis
SANDRA BLANCO, JOSEP BONET, DOLORES LO´PEZ, IRMA CASAS, and RAMO´N ROMERO
Departments of Nephrology and Pathology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; and Intern Department,
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
ACE inhibitors improve nephrin expression in Zucker rats with
glomerulosclerosis.
Background. Podocyte injury is associated with many forms
of human and experimental proteinuric glomerular disease. The
aim of this study was to investigate the level of nephrin expres-
sion in a model of obesity and type II diabetes mellitus, the
obese Zucker rat, as well as to investigate whether nephrin ex-
pression is influenced by treatment with quinapril or diltiazem,
2 drugs frequently used in type II diabetes mellitus.
Methods. Obese Zucker rats were treated with either
quinapril or diltiazem at a dose of 10 mg/kg body weight
per day and 100 mg/kg body weight per day, respectively, for
6 months. Real time reverse transcription-polymerase chain re-
action (RT-PCR) and immunoperoxidase assays were used to
assess and quantify nephrin gene expression and other markers
of podocyte damage, such as desmin and synaptopodin protein.
Results. Quinapril treatment prevented the reduction of
nephrin levels compared with the control group, while dilti-
azem treatment did not prevent the reduction. Similar results
were obtained when other phenotypic markers, such as desmin,
were assessed. Similarly, synaptodin showed this tendency, al-
though it did not achieve statistically significant differences.
Conclusion. The podocyte phenotypic changes assessed in a
model of obesity and type II diabetes mellitus were corrected
by an angiotensin-converting enzyme (ACE) inhibitor. These
results could be associated with an improvement in the slit di-
aphragm, and therefore, in the maintenance of the filtration
barrier. Diltiazem did not achieve similar results.
Podocyte injury is associated with many forms of
human and experimental glomerular disease, including
minimal change disease, focal and segmental glomeru-
losclerosis, membranous glomerulopathy, and diabetes
mellitus [1].
Podocytes may be divided into 3 structurally and func-
tionally different segments: cell body, major processes,
and foot processes (FPs). The basolateral portion of the
foot processes (FP) represents the center of podocyte
function, and is defined by 3 membrane domains: the api-
cal membrane domain, the slit diaphragm (SD) protein
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complex, and the basal membrane domain. The submem-
branous regions of all compartments are connected to the
FP actin cytoskeleton. Interference with any of the 3 do-
mains could lead to changes in the actin cytoskeleton,
resulting in fusion of podocyte FP and obliteration of the
filtration slit [2].
We have previously seen that desmin is an intermediate
filament on podocytes that is expressed only in pathologic
situations of experimental models [3]. Furthermore, it has
been reported in humans that synaptopodin expression
is not part of a primary pathophysiologic mechanism, but
rather, is a secondary phenomenon that reflects the mag-
nitude of the damage [4]. Additionally, nephrin appears
to be an important molecule involved in proteinuria states
and shows a remarkable redistribution from the filtration
slits to the podocyte plasma membrane, such as after in-
duction of puromycin aminonucleoside nephrosis [5].
On the other hand, it has been reported that blockade
of the renin-angiotensin system and blood pressure con-
trol reduces proteinuria and delays glomerulosclerosis.
This action might be associated with the stabilization of
podocytes, and, especially, the SD [6].
Thus, the aim of this study was to investigate the level
of nephrin expression in a model of obesity and type II
diabetes mellitus, using the obese Zucker rat, as well as
to determine whether nephrin expression is influenced by
treatment with quinapril or diltiazem. We also assessed
other markers of podocyte damage (desmin and synap-
topodin) in order to further examine podocyte damage
in this experimental model.
METHODS
Experimental animals and study procedures
Eight-month-old male obese Zucker rats (OZR) were
used. The rats were obtained from IFFA CREDO (Lyon,
France), and were maintained in accordance with the
Catalan Royal Decree. During the study period, the rats
were fed standard chow (A04; Panlab, Barcelona, Spain)
and water ad libitum. Quinapril (10 mg/kg body weight
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per day) and diltiazem (DZM) (100 mg/kg body weight
per day) were provided by Parke Davis, Barcelona, Spain.
The animals were randomly assigned into 3 groups. The
first group consisted of OZR without treatment. The sec-
ond group consisted of OZR that had (N = 8) been given
quinapril since 2 months of age. The third group con-
sisted of OZR (N = 8) that had been given DZM since
2 months of age. All rats were sacrificed at 8 months.
Body weight was determined once a week, and diure-
sis, assessed with 24-hour urine collection, and systolic
blood pressure (SBP), established by the tail-cuff method
with a validated pressure monitor (LE-5001; Letica Sci-
entific Instruments, Barcelona, Spain), were determined
once a month. Fasting blood samples were obtained at
the end of experiment, and biochemical studies (glucose,
cholesterol, triglycerides, creatinine, and total proteins)
were measured with a clinical analyzer (Technicon In-
struments, Tarrytown, NY, USA). The 24-hour urine sam-
ples and urine protein concentrations (mg/day) were also
assessed by Dimension RxL Clinical Chemistry System
(Dade, Newark, NY, USA).
Morphologic studies
The frequency of focal and segmental glomerular scle-
rotic lesions (FGS) was determined by examining all
glomerular profiles as mean ± SD, 100 ± 10/animals con-
tained in a paraffin section from each kidney, as Kasiske
et al [7] and our group previously described.
Desmin and synaptopodin immunoperoxidase staining
Paraffin-embedded kidney sections (4 lm) were pro-
cessed by indirect immunoperoxidase. Primary antibod-
ies were included for desmin (1/50; Dako, Glostrup,
Denmark) and synaptopodin (1/1; RDI Research Diag-
nostics, Inc., Flanders, NJ, USA), respectively. The re-
sults were evaluated in 30 glomeruli per animal and
were expressed as the mean ratios of positive area ver-
sus tuft glomerular area for each glomerulus. Analysis of
glomerular areas was determined by computerized mor-
phometry (Hamamatsu Photonics KN, Hamamatsu City,
Japan).
RNA extraction and cDNA synthesis
Cortical renal tissue stored at –80◦C was homoge-
nized, and total RNA was isolated using an acid guani-
dine thiocyanate-phenol-chloroform extraction method
(Ultraspec, Biotecx Laboratories, Inc., Houston, TX,
USA). The purified RNA was dissolved in DEPC-water
and quantified spectrophotometrically. One microgram
of RNA was then size fractionated by electrophoresis
on a 1% agarose (MS-8; Pronadisa, Madrid, Spain) gel
and visualized with ultraviolet illumination to assess the
integrity of the RNA, and to verify its concentration.
Finally, RNA 5 mg was reverse transcribed to single-
stranded cDNA using a First-Strand cDNA Synthesis Kit
(Pharmacia, Biotech, Stockholm, Sweden) according to
the manufacturer’s instructions. We also made a retro-
transcription of a commercial RNA (total RNA from rat
kidney, Ambion, Austin, TX, USA). This cDNA was used
in amplifications to construct the external curve.
Quantitative real-time RT-PCR
Nephrin gene expression was quantified by real-time
reverse transcription-polymerase chain reaction (RT-
PCR) using the SYBR-Green system based on real-time
detection of accumulated fluorescence (LightCycler-
FastStart DNA Master SYBR GREEN I; Roche Diag-
nostics, Manheim, Germany). Fluorescence for each cycle
was analyzed with a LightCycler termocycler (Roche Di-
agnostics) using an external standard curve made with a
serial dilution of cDNA from a commercial RNA. To con-
trol variation in the amount of cDNA available for PCR
in the different samples, nephrin gene expression was
normalized in relation to the expression of an endoge-
nous control, cyclophilin. LightCycler Probe Design, 1.0
(Roche Diagnostics) was used to construct the sequence-
specific primer. Nephrin and cyclophilin were also tested
at BLAST (NCBI), and neither pseudogenes nor ge-
nomic were found. The forward primer for nephrin was
5′-GCGTAGCTTAGGGACC-3′, and the reverse primer
was 5′CCTAGCCGCCAATCAC-3′. The forward primer
for cyclophilin was 5′-TGA GCA CTG GGG AGA AAG
G-3′, and the reverse primer was 5′-AAA ATG CCC
GCA AGT CAA A-3′. Amplification was performed with
the following time course for nephrin: 95◦C, 10 min, 45
cycles of 94◦C, 10 sec, 58◦C, 10 sec, 72◦C, 10 sec, 1 cy-
cle of 94◦C, 0 sec, 62◦C, 15 sec, 95◦C, 0 sec at 0, 1◦C/sec;
for cyclophilin: 95◦C, 10 min, 35 cycles of 95◦C, 10 sec,
55◦C, 10 sec, 72◦C, 24 sec, 1 cycle of 95◦C, 0 sec, 58◦C,
15 sec, 95◦C, 0 sec at 0, 1◦C/sec. Each sample was tested
in quadruplicate.
Statistical analysis
All results were expressed as mean ± SEM, and P <
0.05 was considered statistically significant in each case.
The Kolmogorov-Smirnov test and the Levene Test were
performed to assess population normality and the ho-
mogeneity of variances, respectively. The mean compar-
isons were performed by one-way analysis of variance
(ANOVA) with contrast coefficients, or Kruskal-Wallis,
when appropriate. To test for associations among the re-
sults, Pearson correlation coefficients were calculated.
Lineal multivariate regression was also performed.
S-12 Blanco et al: Antihypertensive drugs and podocyte injury
OZR Q 8M
groups
DZM 8M
G
lo
m
er
ul
i s
yn
ap
to
po
di
n,
 %
50
45
40
35
30
25
20
15
10
5
0
C
OZR Q 8M
groups
DZM 8M
G
lo
m
er
ul
i d
es
m
in
, %
10
8
6
4
2
0
D
OZR Q 8M
groups
DZM 8M
N
ep
hr
in
 R
NA
 
/ c
yd
op
hi
lin
 R
NA
4
3
2
1
0
B200
175
150
125
100
75
50
25
0
m
g/
24
h
OZR Q 8M
groups
DZM 8M
A
* *
*
* *
Fig. 1. Protein excretion (A), kidney nephrin gene expression (B), synaptopodin protein (C), and desmin protein in nontreated, quinapril-, and
diltiazem (DZM)-treated OZR.
RESULTS
Animal data
At the end of the experiment, OZR had an increased
proteinuria value compared with quinapril treatment
(144 ± 54 vs. 7.3 ± 35, P < 0.05), although not with DZM-
treatment (144 ± 54 vs. 137 ± 33.7, P = NS) (Fig. 1), and
showed a good correlation with glomerulosclerosis (r =
0.641), cholesterol (r = 0.565), and blood pressure (r =
0.436). Serum creatinine values were not influenced by
quinapril or DZM treatment.
Morphologic studies
Morphologic evaluation of kidney tissue demonstrated
consistent glomerular lesions in untreated OZR, involv-
ing on average 11.8% of glomeruli at OZR nontreated
group (Table 1). Glomerular lesions were correlated with
proteinuria (r = 0.641), cholesterol (r = 0.357), and
nephrin (r = −0.359). Animals treated with quinapril
did not exhibit histologic lesions showing a significant
amelioration of glomerular damage. Interestingly, dilti-
azem achieved a 63.5% reduction of the glomerular le-
sions compared with the nontreated group (P = 0.05).
Table 1. Basic characteristics of OZR nontreated and treated groups
Glomerulo-
Blood pressure sclerosis Interstitial Creatinine
mm Hg % infiltrate mg/dL
OZR 8M 149.7 ± 3.4 11.8 ± 2.1 1 ± 0.3 44.4 ± 4.1
Q 8M 147.4 ± 3.4 0.5 ± 1.5a 0.1 ± 0.3a 36.5 ± 4.1
DZM 8M 160.4 ± 3.4a,b 4.3 ± 1.5a 1.9 ± 0.3a,b 38.9 ± 4.3
Abbreviations: OZR, nontreated obese Zucker rats; Q8M, treatment with
quinapril; DZM 8M, treatment with diltiazem. Significance was determined
using ANOVA, where P < 0.05. Data are mean ± SEM.
aValues vs. control.
bQ 8M vs. DZM 8M.
Regarding interstitial infiltrate, quinapril reduced it by
90% (P < 0.05) (Table 1).
Immunoperoxidase staining
The glomerular expression of desmin was notable in
the nontreated group (Fig. 1). Interestingly, desmin ex-
pression was significantly correlated with synaptopodin
(r = 0.559). Furthermore, the glomerular expression of
desmin was only reduced with quinapril (90%). Synap-
topodin expression was similar to desmin positivity.
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Again, the nontreated group expressed moderate levels
of this filament, whereas quinapril treatment diminished
them compared with the OZR group (P = NS). DZM
treatment did not prevent the increase in desmin (P <
0.05) or the synaptopodin reduction (P = NS) (Fig. 1).
Molecular studies
The renal expression of nephrin was assessed in the re-
nal cortex, and analyzed by real-time RT-PCR. Nephrin
expression showed statistically significant changes when
comparing OZR with quinapril treatment (33.6%, P <
0.05), but not when comparing OZR with DZM treat-
ment (15.6%, P = NS). Interestingly, nephrin was corre-
lated with histologic lesions (r = −0.359) (Fig. 1).
DISCUSSION
Podocytes are injured in many forms of human and ex-
perimental glomerular disease, including minimal change
disease, focal and segmental glomerulosclerosis, mem-
branous glomerulopathy, and diabetes mellitus [1]. Addi-
tionally, Coimbra et al [8] proposed that early progressive
podocyte damage and macrophage infiltration is associ-
ated with hyperlipidemia and type IIb diabetes mellitus,
and precedes both the development of glomerulosclero-
sis and tubulointerstitial damage.
Angiotensin-converting enzyme inhibitors (ACEIs)
have uniformly been shown to prevent the development
of both proteinuria and GLS in diabetic rats and humans
[9, 10]. Calcium entry blockers (CCB) are being exten-
sively used to treat systemic hypertension, and to prevent
renal damage. However, the role of CCBs in the preven-
tion of proteinuria and GLS in diabetic rats or human
subjects remains controversial, and only a few studies
with dihidropyridine-CCBs have been described [11, 12].
We recently reported that an ACE inhibitor (quinapril)
and a CCA (DZM), showed differences not only in the
reduction of glomerulosclerosis and proteinuria, but also
in the prevention of podocyte damage assessed with the
desmin marker [3]. These findings could explain the dif-
ferent effects of these drugs on proteinuria.
In the present study, we focused on the podocyte phe-
notypic changes that developed in the obese Zucker rat,
a model of obesity and type II diabetes mellitus. In partic-
ular, we assessed nephrin expression, as well as whether
nephrin expression is influenced by quinapril and dil-
tiazem. We also assessed other markers of podocyte
damage (desmin and synaptopodin) in order to further
evaluate podocyte damage in this experimental model.
Podocytes may be divided into 3 structurally and func-
tionally different segments: cell body, major processes,
and FPs. The basolateral portion of the FPs represents
the center of podocyte function and is defined by 3 mem-
brane domains: the apical membrane domain, the SD
protein complex, and the basal membrane domain. The
submembranous regions of all compartments are con-
nected to the FP actin cytoskeleton. The transmembrane
protein nephrin is the main component of the SD com-
plex. Nephrin could also contribute functional properties
to the SD, perhaps by participating in a protein complex.
Therefore, interference with any of the 3 domains eventu-
ally leads to changes in the actin cytoskeleton, resulting in
fusion of podocyte FP and obliteration of the filtration slit
[2]. Along these lines, Forbes et al [13] reported that a re-
duction in renal nephrin gene and protein expression was
closely associated with the development of albuminuria
in a model of streptozotocin-diabetes and hypertension.
In the present study, the quinapril-treated group
showed a higher expression (33.6%, P < 0.05) than the
nontreated group. The DZM-treated group did not pre-
vent nephrin loss, and presented similar levels to the
nontreated groups. The quinapril treated group totally
prevented proteinuria (94.9% reduction, P < 0.05) and
glomerulosclerosis (95.7% reduction, P < 0.05), whereas
the DZM-treated group only showed a moderate reduc-
tion in glomerulosclerosis (63.5%, P < 0.05) and no re-
duction in proteinuria (4.8%, P > 0.05).
Other authors have evaluated nephrin expression with
different antiproteinuric therapies and have had similar
results. Bonnet et al [14] reported that long-term diabetes
in spontaneously hypertensive rats is associated with a re-
duction in both gene and protein expression of nephrin
within the kidneys. These changes in nephrin levels were
completely prevented by treatment with the angiotensin
II blocker irbesartan, suggesting a potential novel mech-
anism to explain the antiproteinuric effect of agents that
interrupt the renin-angiotensin system. Similarly, Davis
et al [15] explored the effects of the angiotensin II type 1
receptor valsartan and the hydropyridine calcium chan-
nel blocker verapamil, and found that the depletion in
glomerular nephrin expression in diabetic animals was
only abrogated by valsartan treatment, the therapy that
was most effective at retarding the development of al-
buminuria in this model. Finally, Kelly et al [16] found
that ACE inhibition and aminoguanidine both reduced
proteinuria, although only the former attenuated the
diabetes-associated reduction in nephrin expression.
These findings suggest that nephrin reduction may be
a determinant of glomerular hyperpermeability in dia-
betic nephropathy. Attenuation of these changes with
ACE inhibition or with an angiotensin II antagonist treat-
ment suggests that not all classes of drugs reduce uri-
nary protein in diabetic nephropathy through the same
mechanism. Furthermore, several authors have found an
explanation in the mechanism of action of angiotensin.
Hoffmann et al [17] provided direct evidence that in-
creased AT1 signaling in podocytes leads to protein
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leakage and structural podocyte damage, progressing to
focal segmental glomerulosclerosis, in a novel transgenic
rat model with overexpression of the human Ang II type
1 receptor. These results could explain the mechanism by
which ACE inhibitors show more efficacy in the preven-
tion of podocyte damage than other drugs.
Although podocytes can be considered epithelial cells,
rat podocytes contain the muscle-type intermediate fil-
ament protein desmin. It was also reported that the in-
tensity of desmin staining increases during proteinuria
[18], making desmin a potential indicator of glomerular
podocyte stress, although only for rats. In the present
study, the control group tested positive for the pres-
ence of desmin, and quinapril prevented its expression
by 84%. However, DZM treatment not only did not di-
minish desmin, but rather increased it.
In addition to these proteins, some authors [19] re-
ported that synaptopodin (pp44) is also associated with
actin filaments in foot processes, and might be involved
in stabilizing the architecture of the glomerular tuft.
Furthermore, it has been reported [4] in humans that
synaptopodin expression is not a part of the primary
pathophysiologic mechanism, but rather is a secondary
phenomenon that reflects the magnitude of damage. In
the present study, the nontreated group showed an in-
creasing expression of synaptopodin compared with the
quinapril-treated group (21%, P > 0.05). However, as
seen with desmin, DZM treatment did not diminish
synaptopodin, but rather increased it (P > 0.05). These
results show the same tendency as desmin and nephrin,
but do not achieve statistical significance, suggesting that
further studies are needed to determine whether synap-
topodin could be a good marker of podocyte damage.
These findings could argue that the beneficial effects of
angiotensin II inhibition on reduction of proteinuria and
preventing glomerulosclerosis may not simply be a conse-
quence of diminished glomerular capillary pressure, but
may also be due to a direct effect on podocytes [20]. These
results are also in agreement with our previous experi-
mental and clinical experience [3, 21, 22] in which ACE
inhibitors and DZM had different effects in diminishing
proteinuria.
CONCLUSION
The podocyte phenotypic changes assessed in a model
of obesity and type II diabetes mellitus were corrected
by an ACE inhibitor. These results could be associated
with an improvement in the SD, and, therefore, in the
maintenance of the filtration barrier. Diltiazem, however,
did not achieve similar results.
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